Recently, China's biotechnology cutting-edge Zai Lab medicine (Zai Lab) formally applied for listing in the United States, and plans to enter the Nasdaq market (Nasdaq), raising $115 million. Once the news has been confirmed, it has received wide attention in the industry.
Zai Lab medicine is one of the most representative cutting-edge Chinese medicine industry. Since its inception, the company has rapidly established a pipeline of clinical research and development through in-house development and external collaboration. It is worth mentioning that, Zai, Lab medicine has many new drugs into clinical research and development in the middle and late.
One of the leading research drugs in Zai Lab medicine is ZL-2306 (niraparib). Last year, Zai Lab medical and Wuxi partner Tesaro group reached a cooperation agreement to promote the development of the innovation of PARP inhibitors in the China. Later this year, Zai Lab pharmaceuticals will start a phase 3 clinical trial using ZL-2306 as a second-line maintenance therapy for ovarian cancer. In the first half of next year, the new drug is expected to open as a first-line therapy for clinical trials. Zai Lab also plans to start a phase 3 trial in the middle of next year to treat gBRCA positive breast cancer patients with ZL-2306. In addition, the 2 phase of clinical trials using the new drug to treat lung cancer is also under way.
The licensed ZL-2401 (omadacycline) from Paratek Pharmaceuticals is another leading drug in the Zai Lab medicine. This is a new class of tetracycline derivatives that inhibit bacterial protein synthesis and play a role in anti infection. The new drug is expected to be used for acute bacterial skin / skin structure infections (ABSSSI), community acquired bacterial pneumonia (CABP), and urinary tract infections (UTI). Two phase 3 clinical trials for ABSSSI and CABP are in preparation.
In addition to these two drugs, the pipeline Zai Lab medicine there are many potential candidate products: ZL-2301 (brivanib) is a kind of oral, first (first-in-class) selective VEGF receptor and FGF receptor inhibitor is expected to double, the treatment of hepatocellular carcinoma; ZL-3101 (FUGAN) is expected to treat eczema and psoriasis; ZL-2302 as a tyrosine kinase inhibitor, can be targeted to ALK gene mutation, for the treatment of specific patients with non-small cell lung cancer; ZL-1101 can inhibit the OX40 play a key role in the immune response, which is expected to treat graft-versus-host disease.
As many senior analysts have pointed out, the IPO is expected to allow Zai Lab pharmaceuticals to step on the accelerator for new drug research and development". We congratulate Zai Lab medicine from IPO and a step closer, and wish this new successful landing Nasdaq, access to more accelerated research and development resources, so that more new drugs can be released for the benefit of China and even the world's patients.
